Tachycardia is one of the adverse reactions to Lexapro hydrochloride, and the occurrence of this manifestation is abnormal. If there are no clinical symptoms, you can continue to take the drug and observe closely. If the heart rate is too fast and affects the pumping function of the heart, or if there are symptoms such as low blood pressure, angina pectoris or even loss of consciousness, you need to stop taking the drug and go to the hospital immediately. Lercanidipine hydrochloride belongs to the dihydropyridine calcium channel blocker, clinically mainly used in the treatment of essential hypertension, but its antihypertensive effect will reflexively cause the heart rate to accelerate, the patient may produce palpitations, and in severe cases, fainting may occur. When the patient just feels the heartbeat is too fast, and there is no palpitation, chest tightness, angina and other symptoms, there is no need to deal with it for the time being, continue to take the medicine according to the original dose and pay attention to observation. If the patient’s tachycardia develops symptoms such as palpitations, angina or even fainting, it is necessary to stop using the drug immediately and go to the hospital in time to control the heart rate with anti-arrhythmic drugs (e.g., amiodarone, beta-blockers). After it is clear that it is an adverse drug reaction, the dosage of the drug should be adjusted or the drug should be changed under the guidance of a specialist. It should be noted that leucadipine hydrochloride is contraindicated in people who are allergic to the components of the drug, pregnant and lactating women, patients with severe hepatic and renal impairment, patients with left ventricular outflow tract obstruction, patients with unstable angina, patients with untreated heart failure, as well as patients with myocardial infarction of up to one month. When using the drug, it is necessary to closely monitor the adverse reactions, and if there is any discomfort, go to the hospital in time to avoid delaying the condition.